DOI: 10.1093/rheumatology/kead618 ISSN: 1462-0324

The impact of antiphospholipid antibodies/antiphospholipid syndrome on systemic lupus erythematosus

Veronica Venturelli, Ana Mafalda Abrantes, Anisur Rahman, David A Isenberg
  • Pharmacology (medical)
  • Rheumatology


aPLs are a major determinant of the increased cardiovascular risk in patients with SLE. They adversely affect clinical manifestations, damage accrual and prognosis. Apart from the antibodies included in the 2006 revised classification criteria for APS, other non-classical aPLs might help in identifying SLE patients at increased risk of thrombotic events. The best studied are IgA anti-β2-glycoprotein I, anti-domain I β2-glycoprotein I and aPS-PT. Major organ involvement includes kidney and neuropsychiatric systems. aPL/APS severely impacts pregnancy outcomes. Due to increased thrombotic risk, these patients require aggressive cardiovascular risk factor control. Primary prophylaxis is based on low-dose aspirin in high-risk patients. Warfarin is the gold-standard drug for secondary prophylaxis.

More from our Archive